US WorldMeds in the news:

January 2010
US WorldMeds receives approval for the the proprietary name, Revonto™ on January 11, 2010.

November 2009
US WorldMeds is Named 2009 Hot Dozen Company Click here to view.

May 2009
US WorldMeds receives approval for its enhanced reconstituting product, Revonto™, on May 28, 2009.

May 2009
US WorldMeds and Nursing CE Portal Team Up Click here to view.

August 2008
Scientific Reasons Why Normal Saline Cannot Be Used To Reconstitute Dantrolene Sodium For Injection Click here to view.

June 2008
US WorldMeds Completes Phase III Trial of Lofexidine for Treatment of Opiate Withdrawal Symptoms Click here to view.

May 2008
US WorldMeds Completes Development of Instantaneous Reconstitution Dantrolene Sodium for Injection Product. Click here to view.

WINTER 2008
AAAASF Newsletter | ASF SOURCE - (pg7)
US WorldMeds, a closely held Delaware limited liability company, introduces a generic equivalent to Dantrium® IV that is now available through wholesalers and GPOs. Click here to view.

July 2007
US WorldMeds receives FDA approval of its US marketing license (ANDA) for Dantrolene Sodium for Injection. See the Orange Book (“Approved Drug Products with Therapeutic Equivalence Evaluations”). This product is AP rated.

December 2006
The Courier-Journal, US WorldMeds Chief Executive Officer shares vision for company. Click here to review.

October 2006
US WorldMeds announces that it is enrolling study subjects in a Phase 3 clinical trial to determine the safety and efficacy of Lofexidine in relieving the debilitating withdrawal symptoms associated with opiate detoxification. Click here to view.

August 2005
DSM Pharmaceuticals, Inc. and US WorldMeds, LLC announce signing of commercial supply agreement. Click here to view.

January 2004
Visions Newsletter, (see page 2). Click here to view.

November 2003
The Wall Street Journal, November 18 2003. Members of the Wall Street Journal Online can access and view the article by searching under the keyword "detoxify" and date "11/18/03". Peter Sanders is the columnist.

November 2003
Britannia signs agreement with US WorldMeds to bring first non-opiate drug addiction treatment to the US. Click here for a copy of Britannia's press release. (29 KB)

June 2003
New study shows the potential of BritLofex™ in preventing opiate relapse. Click here for a copy of Britannia's press release. (55 KB)

June 2002
Trial of Britannia Pharmaceuticals’ BritLofex™ stopped early due to overwhelming efficacy.
Click here for a copy of Britannia's press release. (47KB)

Meetings/Tradeshows:
US WorldMeds will be exhibiting at the following upcoming meetings/tradeshows. Please give us a call to set up a meeting time, or just stop by our booth.